Clinical trialNCT02582684CompletedPhase 2Interventional

Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients

SponsorAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsEnrollment122HIV-1 Infection

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study was done to see if the combination of two anti-HIV medicines, dolutegravir (DTG, Tivicay) and lamivudine (3TC, Epivir) taken once a day, provide a safe, effective, and well-tolerated treatment for HIV. DTG is a type of HIV medicine called an integrase inhibitor; 3TC is a type of HIV medicine called a reverse transcriptase inhibitor. DTG works by blocking integrase and 3TC works by blocking reverse transcriptase, two HIV proteins (enzymes). This prevents HIV from multiplying and lowers the viral load (amount of HIV in the blood). Both DTG and 3TC are currently part of Food and Drug Administration (FDA) recommended regimens along with a third active drug. Since some HIV medicines have side effects and are costly, there is interest in whether HIV can be successfully controlled with fewer than three HIV drugs.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Babafemi Taiwo, MBBS
Northwestern University
Study Chair
clinicaltrials.gov ↗
Roy Gulick, MD, MPH
Weill Medical College of Cornell University
Study ChairKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

26 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Puerto Rico

Puerto Rico-Aids Crs (5401)
San Juan, Puerto Rico

United States

Ucla Care Center Crs (601)
Los Angeles, California, United States
University of Southern California Crs (1201)
Los Angeles, California, United States
Ucsd, Avrc Crs (701)
San Diego, California, United States
Harbor-Ucla Med. Ctr. Crs (603)
Torrance, California, United States
University of Colorado Hospital Crs (6101)
Aurora, Colorado, United States
Univ. of Miami Aids Crs (901)
Miami, Florida, United States
the Ponce de Leon Center Crs (5802)
Atlanta, Georgia, United States
Northwestern University Crs (2701)
Chicago, Illinois, United States
Rush Univ. Med. Ctr. Actg Crs (2702)
Chicago, Illinois, United States
Brigham and Women'S Hosp. Actg Crs (107)
Boston, Massachusetts, United States
Massachusetts General Hospital Actg Crs (101)
Boston, Massachusetts, United States
Washington University Crs (2101)
St Louis, Missouri, United States
Columbia Physicians and Surgeons Crs (30329)
New York, New York, United States
Cornell Crs (7804)
New York, New York, United States
Weill Med. College of Cornell Univ., the Cornell Ctu -Chelsea (7803)
New York, New York, United States
University of Rochester Adult Hiv Therapeutic Strategies Network Crs (31787)
Rochester, New York, United States
3201 Chapel Hill Crs
Chapel Hill, North Carolina, United States
Greensboro Crs (3203)
Greensboro, North Carolina, United States
Univ. of Cincinnati Crs (2401)
Cincinnati, Ohio, United States
the Ohio State Univ. Aids Crs (2301)
Columbus, Ohio, United States
Hosp. of the Univ. of Pennsylvania Crs (6201)
Philadelphia, Pennsylvania, United States
the Miriam Hospital Actg Crs (2951)
Providence, Rhode Island, United States
Vanderbilt Therapeutics Crs (3652)
Nashville, Tennessee, United States
31443 Trinity Health and Wellness Center Crs
Dallas, Texas, United States
Houston Aids Research Team Crs (31473)
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dolutegravir →Lamivudine →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 8 Dec 2015
Primary completion: 28 Feb 2017
Completion: 26 Sept 2017
Last update posted: 9 May 2018
Registered enrollment: 122
Registry id: NCT02582684

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.